BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 33387580)

  • 21. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 22. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
    Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
    ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
    Tiwari P; Khan H; Singh TG; Grewal AK
    Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification.
    Rouleau-Turcotte É; Pascal JM
    J Biol Chem; 2023 Dec; 299(12):105397. PubMed ID: 37898399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP-1 involvement in neurodegeneration: A focus on Alzheimer's and Parkinson's diseases.
    Martire S; Mosca L; d'Erme M
    Mech Ageing Dev; 2015 Mar; 146-148():53-64. PubMed ID: 25881554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.
    Kam CM; Tauber AL; Levonis SM; Schweiker SS
    Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly(ADP-ribose)polymerase-1 hyperactivation in neurodegenerative diseases: The death knell tolls for neurons.
    Narne P; Pandey V; Simhadri PK; Phanithi PB
    Semin Cell Dev Biol; 2017 Mar; 63():154-166. PubMed ID: 27867042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
    Badawy AA
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33063092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
    Kauppinen TM
    Neurochem Int; 2007 Jun; 50(7-8):954-8. PubMed ID: 17222947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors.
    Zheng M; Mex M; Götz KH; Marx A
    Org Biomol Chem; 2018 Nov; 16(46):8904-8907. PubMed ID: 30203829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avoid the trap: Targeting PARP1 beyond human malignancy.
    Kim C; Chen C; Yu Y
    Cell Chem Biol; 2021 Apr; 28(4):456-462. PubMed ID: 33657415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
    Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
    BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis.
    Liu L; Li J; Ke Y; Zeng X; Gao J; Ba X; Wang R
    Cell Mol Life Sci; 2022 Jan; 79(1):60. PubMed ID: 35000037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.
    Lakatos P; Hegedűs C; Salazar Ayestarán N; Juarranz Á; Kövér KE; Szabó É; Virág L
    Mutat Res; 2016 Aug; 790():31-40. PubMed ID: 27427773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.
    Karpova Y; Wu C; Divan A; McDonnell ME; Hewlett E; Makhov P; Gordon J; Ye M; Reitz AB; Childers WE; Skorski T; Kolenko V; Tulin AV
    Biochem Pharmacol; 2019 Sep; 167():149-162. PubMed ID: 30880062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection.
    Kotova E; Tulin AV
    Methods Mol Biol; 2017; 1608():299-312. PubMed ID: 28695517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
    Andronikou C; Rottenberg S
    Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.